Attovia Therapeutics, Inc. (ATTO)
Attovia Therapeutics will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Company Description
Attovia Therapeutics is a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need.
Our lead pipeline candidates target commercially validated pathways and are designed through our ATTOBODY biologics platform to deliver improved treatments relative to the current standards of care.
Leveraging our ATTOBODY platform, we have nominated three product candidates within our first two years, including one currently in the clinic, ATTO-1310.
ATTO-1310 is an ATTOBODY-based therapeutic targeting interleukin-31 (IL-31) that completed dosing in a Phase 1 clinical trial in healthy volunteers (HVs) and patients in the first quarter of 2026.
Attovia Therapeutics, Inc.
| Country | United States |
| Founded | 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 44 |
| CEO | Tao Fu |
Contact Details
Address: 1091 Industrial Road, Suite 310 San Carlos, CA 94070 United States | |
| Phone | (510) 399-5001 |
| Website | attovia.com |
Stock Details
| Ticker Symbol | ATTO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 2058707 |
Key Executives
| Name | Position |
|---|---|
| Tao Fu | Chief Executive Officer, President and Director |
| Zaneta Odrowaz, Ph.D. | Chief Business Officer, Treasurer, Secretary |
| Steven Chan | Chief Financial Officer |
| Petter Veiby | Chief Scientific Officer |
| Hubert Chen, M.D. | Chief Medical Officer |
| James Topper, M.D., Ph.D. | Chairman and Director |
| Mitchell Gold, M.D. | Director |
| Rebecca Luse. | Director |
| Aaron Royston, M.D. | Director |
| John W. Smither | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 14, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jun 5, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Feb 12, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Dec 19, 2025 | DRS | [Cover] Draft Registration Statement |